Dr Reddy’s Q4 Profit Jumps 22% to ₹1,594 Crore

12 May 2025 , 01:00 PM

Dr. Reddy’s Laboratories, a prominent pharmaceutical firm based in Hyderabad, reported third-quarter figures for 2025 on Friday, 9th May. Its net earnings increased 22% over the last corresponding quarter. Dr. Reddy’s made a profit of ₹1,594 crore for this quarter, versus a profit of ₹1,307 crores for the last year. Revenue also increased, rising 8.6% year over year to ₹8,506 crore, indicating consistent business growth.

One of the positives was the robust jump in EBITDA, which rose by almost 59% to ₹2,975 crore, a sign of increased operating efficiency. The EBITDA margin, a measure of the degree to which costs are being managed by the company, rose to 29.1%, an astonishing 510 basis points improvement over last year’s comparable period.

Back to the shareholders, the board has also recommended a final dividend of ₹8 per equity share for FY 2024–25. The dividend record date is July 10, 2025, so only shareholders of record on that date will be eligible.